Cisplatin-treated murine peritoneal macrophages induce apoptosis in L929 cells: Role of Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 187-196

  Chauhan, Puja ^a   Sodhi, Ajit ^a   Tarang, Shikha ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Apoptosis; Cisplatin; Fas Fas ligand; L929 cells; Macrophages; Tumor necrosis factor tumor necrosis factor receptor 1

Indexed keywords

CAD PROTEIN; CASPASE 3; CASPASE 8; CISPLATIN; CYTOCHROME C; DNA FRAGMENT; FAS LIGAND; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; FEMALE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; STAINING; WESTERN BLOTTING;

ANIMALS; ANNEXIN A5; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; COCULTURE TECHNIQUES; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEMALE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NEOPLASM PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTORS;

EID: 33845710269     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280104b11     Document Type: Article

References (48)

1. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984; 2:283-318.
2. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993; 361:359-362.
3. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM. Enhanced antigen presentation using human Fc gamma receptor (monocyte/ macrophage)-specific immunogens. J Immunol 1992; 149:3477-3481.
4. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141:2407-2412.
5. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221:865-867.
6. Te Velde AA, Figdor CG. Monocyte mediated cytotoxic activity against melanoma. Melanoma Res 1992; 1:303-309.
7. Singh SM, Sodhi A. Interaction between cisplatin treated macrophages and dalton's lymphoma cells in vitro. Exp Cell Biol 1988; 56:1-11.
8. Singh RK, Sodhi A, Singh SM. Production of Interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophage. Nat Immun Cell Growth Regul 1991; 10:105-116.
9. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expressions by human mononuclear phagocytes: a review. Mol Med 1998; 4:557-591.
10. MacMicking JQ, Xie W, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-350.
11. Feinman RD, Henriksen-DeStefano D, Tsujimoto M, Vilcek J. Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 1987; 138:635-640.
12. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-367.
13. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267:1449-1456.
14. Caricchio R, Reap E, Cohen P. Fas/Fas ligand interactions are involved in UV-B-induced human lymphocyte apoptosis. J Immunol 1998; 161:241-251.
15. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574-577.
16. Ichinose Y, Bakouche O, Tsao JY, Fidler IJ. Tumor necrosis factor and IL-1 associated with plasma membrane of activated human monocytes lyse monokine sensitive but not monokine resistant tumor cells whereas viable activated monocytes lyse both. J Immunol 1988; 141:512-518.
17. Martin F, Olson NO, Jeannin JF. Effect for four agents that modify microtubule and microfilaments (vinblastine, colchicine, lidocaine and cytochalasin B) on macrophage mediated cytotoxicity to tumor cells. Cancer Immunol Immun 1981; 10:113-120.
18. Ingrid H, Klaus-Michael D. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-2614.
19. Grell M, Krammer PH, Scheurich P. Segregation of APO-1/Fas antigen and tumor necrosis factor receptor-mediated apoptosis. Eur J Immunol 1994; 24:2563-2566.
20. Nils H, Rossana Z, Oliver M, Margot T, Antoine A, Salvatore V, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1:489-495.
21. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol 2005; 148:107-121.
22. Razzaque MS, Koji T, Kumatori A, Taguchi T. Cisplatin induced apoptosis in human proximal tubular epithelial cell is associated with the activation of the Fas/FasL system. Histochem Cell Biol 1999; 111:359-365.
23. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528-530.
24. Tracey K, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45:491-503.
25. Chen G, Goeddel DV. TNFR1 signaling: a beautiful pathway. Science 2002; 296:1634-1635.
26. Decker T, Lomann-Mathes M, Gifford GE. Cell associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987; 138:957-962.
27. Peschon JJ, Torrance KL, Stocking MB, Glaccum C, Otten CR, Wills K, et al. TNF receptor-deficient mice divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160:943-952.
28. Grell M, Douni E, Wajant H, Londen M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793-802.
29. Bang S, Jeong EJ, Kim IK, Jung YK, Kim KS. Fas and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction. J Biol Chem 2000; 275:36217-36222.
30. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81:505-512.
31. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MOR1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85:803-815.
32. Enari M, Hideki S, Yokoyama H, Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades NA during apoptosis, and its inhibitor ICAD. Nature 1998; 391:43-50.
33. Li H, Zhu H, Xu CJ, Yaun J. Cleavage of BID by caspase8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491-501.
34. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481-490.
35. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987; 139:3199-3206.
36. Kerr J, Wyllie AH, Currie AR. Apoptosis is a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 68:239-257.
37. Chen GC, Chu YS, Chak EC, Leung BC, Poon WS. Induction of apoptosis in glioma cells by molecules released from activated macrophages. J Neuro-Oncol 2002; 57:179-186.
38. Strasser A. Dr. Josef Steiner Cancer Research prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int J Cancer 1999; 81:505-511.
39. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A 1986; 83:5233-5237.
40. Bin LU, Wang L, Medan D, Toledo D, Huang C, Chen F, et al. Regulation of Fas(CD95)-induced apoptosis by nuclear factor-kB and tumor necrosis factor-α in macrophages. Am J Physiol Cell Physiol 2002; 283:831-838.
41. Varfolomeev EE, Boldin MP, Goncharov TM, Wallach D. A potential mechanism of cross talk between the p55 tumor necrosis factor receptor and Fas/APO-1 proteins binding to the death domain of the two receptors also bind to each other. J Exp Med 1996; 183:1271-1275.
42. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57:1758-1768.
43. Golstein P. Fas-based T-cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995; 198:25-37.
44. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85:757-764.
45. Hsu J, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84:299-308.
46. Fishman M. Cytolytic activities of activated macrophages versus paraformaldehyde- fixed macrophages; soluble versus membrane-associated TNF. Cell Immunol 1991; 137:164-174.
47. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Michael K. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to cell contact. Cell 1990; 63:251-258.
48. Kriegler M, Perez C, Defay K, Albert I, Lu SD. A novel from TNF/cachectin as a cell surface cytotoxic transmembrane protein: ramification of complex physiology of TNF. Cell 1988; 53:45-53.